Travere Therapeutics, Inc. Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

TVTX

Peringkat dalam Saham #3417
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Harga Saham
$52.53
Kapitalisasi Pasar
$4.95B
Perubahan (1 hari)
-0.10%
Perubahan (1 tahun)
91.16%
Negara
US
Perdagangan Travere Therapeutics, Inc. (TVTX)

Kategori

Healthcare
Riwayat harga saham Travere Therapeutics, Inc. (TVTX)
Harga penutupan tertinggi: $53.28 pada 2026-10-01

Harga penutupan terendah: $1.88 pada 2012-11-01
Riwayat harga saham Travere Therapeutics, Inc. dari 2012 hingga 2026
Performa harga saham tahunan
Tahun Performa
2026 (TTM) 21.73%
2025 98.56%
2024 113.02%
2023 -57.16%
2022 -32.13%
2021 10.99%
2020 87.35%
2019 -40.02%
2018 7.59%
2017 9.33%
2016 -3.75%
2015 81.19%
2014 54.72%
2013 74.64%
2012 0.00%
Harga saham perusahaan atau pesaing serupa
Perusahaan Harga saham Perubahan 1th% Negara
$525.12 23.14%
US
$237.61 784.95%
US
$137.83 -3.78%
AU
$887.75 9.04%
NL
$289.96 1.88%
BE